$XCUR
Exicure Inc

2017 Q4 Form 10-Q Financial Statement

#000162828017011566 Filed on November 14, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q3
Revenue $2.095M $2.497M $0.00
YoY Change 203.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.240M $1.270M $850.0K
YoY Change 180.0% 49.41%
% of Gross Profit
Research & Development $2.830M $3.121M $2.413M
YoY Change -46.9% 29.34%
% of Gross Profit
Depreciation & Amortization $70.00K $70.00K $130.0K
YoY Change 40.0% -46.15%
% of Gross Profit
Operating Expenses $5.070M $4.391M $3.262M
YoY Change -17.29% 34.61%
Operating Profit -$1.894M -$3.262M
YoY Change -41.94%
Interest Expense -$180.0K $201.0K $208.0K
YoY Change -14.29% -3.37%
% of Operating Profit
Other Income/Expense, Net $50.00K -$38.00K -$264.0K
YoY Change 400.0% -85.61%
Pretax Income -$3.100M -$1.930M -$3.530M
YoY Change -45.04% -45.33%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.443M -$1.932M -$3.526M
YoY Change -38.95% -45.21%
Net Earnings / Revenue -164.34% -77.37%
Basic Earnings Per Share
Diluted Earnings Per Share -$78.88K -$49.11K -$89.82K
COMMON SHARES
Basic Shares Outstanding 39.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.80M $22.90M
YoY Change
Cash & Equivalents $25.76M $22.94M $14.07M
Short-Term Investments
Other Short-Term Assets $1.800M $1.100M
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00 $200.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $27.64M $24.28M
YoY Change 37.91%
LONG-TERM ASSETS
Property, Plant & Equipment $1.317M $1.059M
YoY Change 161.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $32.00K $32.00K
YoY Change 0.0%
Total Long-Term Assets $1.349M $1.091M
YoY Change 152.15%
TOTAL ASSETS
Total Short-Term Assets $27.64M $24.28M
Total Long-Term Assets $1.349M $1.091M
Total Assets $28.99M $25.37M
YoY Change 40.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.049M $2.379M
YoY Change 106.09%
Accrued Expenses $1.273M $2.496M
YoY Change -41.06%
Deferred Revenue $1.034M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $2.551M
YoY Change -100.0%
Total Short-Term Liabilities $3.356M $10.53M
YoY Change -72.4%
LONG-TERM LIABILITIES
Long-Term Debt $4.855M $2.670M
YoY Change 9.0%
Other Long-Term Liabilities $278.0K $279.0K
YoY Change -1.07%
Total Long-Term Liabilities $5.133M $2.949M
YoY Change 8.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.356M $10.53M
Total Long-Term Liabilities $5.133M $2.949M
Total Liabilities $9.012M $13.69M
YoY Change -50.29%
SHAREHOLDERS EQUITY
Retained Earnings -$33.62M -$31.54M
YoY Change 48.71%
Common Stock $4.000K $4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.98M $11.68M
YoY Change
Total Liabilities & Shareholders Equity $28.99M $25.37M
YoY Change 40.88%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$3.443M -$1.932M -$3.526M
YoY Change -38.95% -45.21%
Depreciation, Depletion And Amortization $70.00K $70.00K $130.0K
YoY Change 40.0% -46.15%
Cash From Operating Activities -$5.340M -$4.000M -$10.68M
YoY Change -194.85% -62.55%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$340.0K -$320.0K
YoY Change 185.71% 6.25%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$200.0K -$340.0K -$320.0K
YoY Change 185.71% 6.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.370M 18.45M 6.330M
YoY Change 83600.0% 191.47%
NET CHANGE
Cash From Operating Activities -5.340M -4.000M -10.68M
Cash From Investing Activities -200.0K -340.0K -320.0K
Cash From Financing Activities 8.370M 18.45M 6.330M
Net Change In Cash 2.830M 14.11M -4.670M
YoY Change -49.19% -402.14%
FREE CASH FLOW
Cash From Operating Activities -$5.340M -$4.000M -$10.68M
Capital Expenditures -$200.0K -$340.0K -$320.0K
Free Cash Flow -$5.140M -$3.660M -$10.36M
YoY Change -190.18% -64.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001698530
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39300823 shares
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
EXICURE, INC.
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
509000 USD
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2379000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2160000 USD
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2496000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
123000 USD
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1004000 USD
CY2012Q1 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
52000 USD
CY2016Q4 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
50000 USD
CY2017Q3 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
48000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
617000 USD
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
776000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
-17578000 USD
CY2017Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43219000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1104000 USD
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
167000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
507000 USD
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
362000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M0D
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
67000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1104000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
137000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
150000 USD
CY2016Q4 us-gaap Assets
Assets
20576000 USD
CY2017Q3 us-gaap Assets
Assets
25371000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
20041000 USD
CY2017Q3 us-gaap Assets Current
AssetsCurrent
24280000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18731000 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14068000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19623000 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22936000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4663000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3313000 USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30782380 shares
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131644 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35513987 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131644 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35513987 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2017Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5404000 USD
CY2017Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
164000 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
231000 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
CY2017Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
19000 USD
CY2016Q4 us-gaap Deferred Revenue
DeferredRevenue
9310000 USD
CY2017Q3 us-gaap Deferred Revenue
DeferredRevenue
3103000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8276000 USD
CY2017Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3103000 USD
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1034000 USD
CY2017Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 USD
CY2016Q3 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
46000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
132000 USD
CY2017Q3 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
70000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
159000 USD
CY2016Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
15000 USD
CY2017Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
13000 USD
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-36.09
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-103.15
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.34
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-48.73
CY2016Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-726000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6329000 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
423000 USD
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
513000 USD
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2352000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-201000 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
849000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2736000 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1270000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4806000 USD
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-359000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1361000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-948000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6207000 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-49000 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-2000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
151000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
727000 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-237000 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
201000 USD
CY2016Q3 us-gaap Interest Expense
InterestExpense
208000 USD
us-gaap Interest Expense
InterestExpense
516000 USD
CY2017Q3 us-gaap Interest Expense
InterestExpense
201000 USD
us-gaap Interest Expense
InterestExpense
616000 USD
CY2016Q3 us-gaap Interest Paid
InterestPaid
153000 USD
us-gaap Interest Paid
InterestPaid
327000 USD
CY2017Q3 us-gaap Interest Paid
InterestPaid
158000 USD
us-gaap Interest Paid
InterestPaid
470000 USD
CY2014Q4 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P6Y
CY2016Q4 us-gaap Liabilities
Liabilities
18128000 USD
CY2017Q3 us-gaap Liabilities
Liabilities
13689000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20576000 USD
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25371000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12158000 USD
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10529000 USD
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
5667000 USD
CY2017Q3 us-gaap Long Term Debt
LongTermDebt
5221000 USD
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1213000 USD
CY2017Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2551000 USD
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4454000 USD
CY2017Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2670000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
48000 USD
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2172000 USD
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2620000 USD
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
612000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
657843 shares
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18486000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-315000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10677000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14447000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.92
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-3526000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11299000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-2313000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8937000 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-264000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-580000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-38000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-476000 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
3262000 USD
us-gaap Operating Expenses
OperatingExpenses
11065000 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
4772000 USD
us-gaap Operating Expenses
OperatingExpenses
16085000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3262000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10719000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2275000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8461000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1184000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
59000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
353000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
347000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
341000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
84000 USD
CY2016Q3 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
83000 USD
us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
191000 USD
CY2017Q3 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
77000 USD
us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
232000 USD
CY2016Q3 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
83000 USD
us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
216000 USD
CY2017Q3 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
83000 USD
us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
249000 USD
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
166000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
407000 USD
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
160000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
481000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
114000 USD
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
979000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32000 USD
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32000 USD
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
281000 USD
CY2017Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
279000 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2131730 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.37
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
315000 USD
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-56000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-64000 USD
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
163000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
140000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
141000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
726000 USD
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
403000 USD
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1130000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20302000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
6000000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
450000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
26000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
43000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000 USD
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1835000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
503000 USD
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1059000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
595000 USD
CY2017Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
428000 USD
us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
1417000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2413000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8329000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3502000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11279000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22604000 USD
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31541000 USD
CY2016Q3 us-gaap Revenue From Grants
RevenueFromGrants
0 USD
us-gaap Revenue From Grants
RevenueFromGrants
346000 USD
CY2017Q3 us-gaap Revenue From Grants
RevenueFromGrants
0 USD
us-gaap Revenue From Grants
RevenueFromGrants
0 USD
CY2016Q3 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
346000 USD
CY2017Q3 us-gaap Revenues
Revenues
2497000 USD
us-gaap Revenues
Revenues
7624000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
507000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1104000 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
4.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3089352 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3678359 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3595855 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
202000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
10396 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
9143000 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
5257000 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.25
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.79
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
5195000 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.77
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.75
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.00
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.21
CY2017Q3 us-gaap Share Price
SharePrice
4.21
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3704000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y8M12D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
58440 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17055000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
43000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
2448000 USD
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
11682000 USD
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2016Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
0 USD
CY2017Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
201000 USD
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
97691 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
109539 shares
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1725906 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
183395 shares
CY2016Q4 xcur Accrued License Agreement Fees Current
AccruedLicenseAgreementFeesCurrent
1500000 USD
CY2017Q3 xcur Accrued License Agreement Fees Current
AccruedLicenseAgreementFeesCurrent
0 USD
CY2016Q3 xcur Collaboration Agreement Revenue
CollaborationAgreementRevenue
0 USD
xcur Collaboration Agreement Revenue
CollaborationAgreementRevenue
0 USD
CY2017Q3 xcur Collaboration Agreement Revenue
CollaborationAgreementRevenue
2497000 USD
xcur Collaboration Agreement Revenue
CollaborationAgreementRevenue
7624000 USD
CY2017Q3 xcur Common Stock Voting Rightsfor Each Share
CommonStockVotingRightsforEachShare
1 vote_per_share
CY2016Q4 xcur Common Stock Warrant Liability
CommonStockWarrantLiability
0 USD
CY2017Q3 xcur Common Stock Warrant Liability
CommonStockWarrantLiability
211000 USD
CY2017Q3 xcur Estimated Fair Valueof Common Stock Per Share
EstimatedFairValueofCommonStockPerShare
3.00
xcur Fair Value Assumptions Impact Of10 Percent Change In Expected Volatility Rate
FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate
18000 USD
xcur Fair Value Assumptions Impact Of10 Percent Change In Fair Value Of Common Stock
FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock
34000 USD
xcur Issuance Of Common Stock Warrants
IssuanceOfCommonStockWarrants
0 USD
xcur Issuance Of Common Stock Warrants
IssuanceOfCommonStockWarrants
211000 USD
xcur Issuanceof Preferred Stock Warrants
IssuanceofPreferredStockWarrants
134000 USD
xcur Issuanceof Preferred Stock Warrants
IssuanceofPreferredStockWarrants
0 USD
xcur Payments Of Common Stock Financing Costs
PaymentsOfCommonStockFinancingCosts
0 USD
xcur Payments Of Common Stock Financing Costs
PaymentsOfCommonStockFinancingCosts
1264000 USD
xcur Payments Of Preferred Stock Financing Costs
PaymentsOfPreferredStockFinancingCosts
6000 USD
CY2016Q4 xcur Preferred Stock Warrant Liability
PreferredStockWarrantLiability
201000 USD
xcur Payments Of Preferred Stock Financing Costs
PaymentsOfPreferredStockFinancingCosts
0 USD
xcur Paymentsfor License Agreements
PaymentsforLicenseAgreements
3247000 USD
xcur Preferred Stock Liquidation Preference Percent Of Aggregate Cash Contributions
PreferredStockLiquidationPreferencePercentOfAggregateCashContributions
1.5
xcur Share Conversion During Period Value In Connection With Merger
ShareConversionDuringPeriodValueInConnectionWithMerger
-31000 USD
xcur Stock Issuance Costs Incurred During Noncashor Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction
0 USD
xcur Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate
SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
0.05
xcur Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate
SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
0.05
CY2017Q3 xcur Preferred Stock Warrant Liability
PreferredStockWarrantLiability
0 USD
CY2017Q3 xcur Price Based Anit Dilution Protection Gross Proceeds Threshold
PriceBasedAnitDilutionProtectionGrossProceedsThreshold
40000000 USD
CY2017Q3 xcur Retained Earnings Accumulated Deficit Inceptionto Date
RetainedEarningsAccumulatedDeficitInceptiontoDate
-50378000 USD
xcur Stock Issuance Costs Incurred During Noncashor Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction
1773000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. As of September 30, 2017 and December 31, 2016, the Company had cash and cash equivalents of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$22,936</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$19,623</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. The cash balances at each respective period were maintained at two institutions. These deposits exceed federally insured limits.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is currently not profitable and no assurance can be provided that it will ever be profitable. The Company&#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues. See also Note 1, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Description of Business and Basis of Presentation&#8212;Liquidity Risk</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for more information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution. The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.</font></div></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates. </font></div></div>

Files In Submission

Name View Source Status
0001628280-17-011566-index-headers.html Edgar Link pending
0001628280-17-011566-index.html Edgar Link pending
0001628280-17-011566.txt Edgar Link pending
0001628280-17-011566-xbrl.zip Edgar Link pending
exicure10q93017.htm Edgar Link pending
exicureexhibit311-93017.htm Edgar Link pending
exicureexhibit312-93017.htm Edgar Link pending
exicureexhibit321-93017.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xcur-20170930.xml Edgar Link completed
xcur-20170930.xsd Edgar Link pending
xcur-20170930_cal.xml Edgar Link unprocessable
xcur-20170930_def.xml Edgar Link unprocessable
xcur-20170930_lab.xml Edgar Link unprocessable
xcur-20170930_pre.xml Edgar Link unprocessable